Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma

NCT03336606 is registered in ClinicalTrials.gov with Providence Health & Services as lead sponsor.

NCT NCT03336606
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03336606 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma
Lead sponsor
Providence Health & Services
Phase
Phase 1
Overall status
Completed
Start date
July 25, 2018
Completion date
May 14, 2026
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, squamous cell, cell cancer, squamous, head and neck cancer, head and neck squamous cell carcinoma, melanoma